Tph Cell Targeting in Autoimmune Disease Therapy
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods fail to effectively characterize and target CD4+ T helper cells involved in autoimmune diseases like rheumatoid arthritis and systemic lupus erythematosus, due to limited access to human tissues and incomplete knowledge of autoantigen-specific T cells.
Innovation Solution
Identification and characterization of peripheral helper T cells (Tph cells) with specific markers such as CD4+, PD-1hi, CXCR5−, CCR2+, CCR5+, CX3CR1+, MHC Class II+, and ICOS+, which drive pathologic B cell responses and autoantibody production, using mass cytometry and transcriptional analyses, and development of agents to deplete or inhibit these cells selectively.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If global B cell or T cell modulation strategies are used, then disease activity is reduced, but lack of precision in targeting specific pathogenic cells remains
Solution Approach 1:
The patent segments the broad T cell population into specific subsets based on marker expression patterns. Tph cells are identified by the specific phenotype CD4+PD-1hiCXCR5−CCR2+CCR5+CX3CR1+, distinguishing them from other CD4+ T cell subsets. This segmentation enables targeted therapy against the specific pathogenic subset rather than all T cells, resolving the contradiction between therapeutic precision and targeting complexity by providing clear phenotypic definitions for selective targeting.
Solution Approach 2:
The patent applies local quality by assigning different marker expressions to different T cell functional states. The Tph cell subset exhibits a unique local quality profile (PD-1hi, CXCR5−, CCR2+, CCR5+, CX3CR1+) that marks them as pathogenic in specific autoimmune contexts. This localized phenotypic characterization allows selective targeting of Tph cells while preserving other T cell subsets, achieving precision without requiring complex multi-parameter targeting systems.
2Measurement precision
If Tph cells are selectively depleted using multiple marker targeting, then specificity is improved, but device and assay complexity increases
Solution Approach 1:
The patent employs mass cytometry (CyTOF) as a universal platform that can simultaneously measure multiple protein markers (PD-1, CXCR5, CCR2, CCR5, CX3CR1, ICOS, MHCII) on single T cells. This multi-functional technology provides high measurement precision for identifying Tph cells by their specific marker profile while consolidating what would otherwise require multiple separate assays into a single comprehensive platform, thereby managing complexity through technological integration rather than multiplication.
3Quantity of substance
If limited access to human tissues is overcome by developing new access methods, then tissue sample availability improves, but procedural complexity and risk increase
Solution Approach 1:
The patent uses synovial fluid as an intermediary accessible compartment that reflects the Tph cell population in the harder-to-access synovial tissue. Since synovial fluid can be obtained via simple arthrocentesis rather than invasive tissue biopsy, it serves as a practical mediator for studying Tph cells in rheumatoid arthritis. The Tph cell phenotype and frequency in synovial fluid mirror those in synovial tissue, providing adequate sample availability without the procedural complexity and risks of direct tissue access.
Data Source
AI summary
This disclosure provides methods and compositions for detecting Tph cells and/or reducing the number (or frequency) and/or activity of such cells in order to provide therapeutic benefit to a subject having or at risk of developing an autoantibody-associated condition such as an autoantibody-associated autoimmune disease.